8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 3, 2016

VITAE PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of Incorporation) 001-36617
(Commission File Number) 04-3567753
(IRS Employer Identification No.)

502 West Office Center Drive
Fort Washington, PA 19034
(Address of Principal Executive Offices) 19034
(Zip Code)

Registrant’s telephone number, including area code: (215) 461-2000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02.   Results of Operations and Financial Condition.

On August 3, 2016, Vitae Pharmaceuticals, Inc. (the “Company” or “Vitae”) issued a press release and is holding a conference call and webcast regarding its results of operations and financial condition for the quarter ended June 30, 2016. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Various statements to be made during the conference call are “forward-looking statements” under the securities laws, including, but not limited to, statements regarding Vitae’s plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.

Important factors that could cause actual results to differ materially from those reflected in Vitae’s forward-looking statements include, among others, the timing of enrollment for its clinical trials, commencement and completion of Vitae’s clinical trials; the timing and success of preclinical studies and clinical trials conducted by Vitae and its development partners; the scope, progress, expansion, and costs of developing and commercializing Vitae’s current or future product candidates; the size and growth of the potential markets for Vitae’s current or future product candidates and the ability to serve those markets; Vitae’s expectations regarding Vitae’s expenses and revenue, the sufficiency of Vitae’s cash resources and needs for additional financing; Vitae’s ability to establish and maintain development partnerships; the ability to obtain and maintain regulatory approval of Vitae’s product candidates, and the labeling for any approved products; the rate and degree of market acceptance of any of Vitae’s current or future product candidates; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vitae’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov. Additional information will also be set forth in those sections of Vitae’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, which will be filed with the SEC in the third quarter of 2016.

In addition to the risks described above and in Vitae’s other filings with the SEC, other unknown or unpredictable factors could also affect Vitae’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information conveyed on the conference call is provided only as of the date of the call, and Vitae undertakes no obligation to update any forward-looking statements presented on the call on account of new information, future events, or otherwise, except as required by law.

The information in Item 2.02 of this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01.   Regulation FD.

As set forth in Item 2.02, Vitae will be holding a conference call and webcast on August 3, 2016.  A copy of the presentation being used in connection with this conference call and webcast is furnished herewith as Exhibit 99.2 and is incorporated by reference herein.

2

The information included in this Current Report on Form 8-K pursuant to Item 7.01, including Exhibit 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.   Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
99.1	Vitae Pharmaceuticals, Inc., Press Release, dated August 3, 2016
99.2	Presentation Slides Accompanying August 3, 2016 Vitae Pharmaceuticals Inc. Webcast

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VITAE PHARMACEUTICALS, INC.
Date:  August 3, 2016	By:	/s/ Jeffrey S. Hatfield
		Jeffrey S. Hatfield
		Chief Executive Officer

4

EX-99.1

Exhibit 99.1

Vitae Pharmaceuticals Reports Second Quarter 2016
Operating and Financial Results

Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016

Conference call scheduled for 4:30 p.m. EDT today

FORT WASHINGTON, PA, August 3, 2016 — Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended June 30, 2016.

Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, “During the quarter, we made significant progress towards the completion of two key milestones for Vitae. First, we are on track to report top-line results for the ongoing Phase 2a proof-of-concept study for VTP-38543, our wholly owned, potential first-in-class LXRβ selective agonist being developed for atopic dermatitis, in the fourth quarter of 2016. Second, we continue to finalize plans for the next clinical trial, expected to initiate in the fourth quarter of 2016, of VTP-43742, our wholly owned, first-in-class RORγt inhibitor, in psoriasis patients. Previously, VTP-43742 demonstrated results that validated RORγt as a therapeutic target for psoriasis and VTP-43742 as a potentially paradigm-changing therapeutic.”

Quarterly and Recent Highlights

Pipeline Updates:

VTP-38543 in Atopic Dermatitis

·Continued enrollment in its Phase 2a proof-of-concept clinical trial of VTP-38543 in atopic dermatitis. This four-week, randomized, double-blind, placebo-controlled Phase 2a trial will assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple ascending topical doses of VTP-38543 in approximately 100 adult patients with mild to moderate atopic dermatitis. Vitae expects to report top-line efficacy results in the fourth quarter of 2016.

VTP-43742 in Autoimmune Disorders

·Continued preparations for an upcoming Phase 2 clinical trial of VTP-43742 in psoriasis patients. Vitae plans to advance VTP-43742 into a 16-week Phase 2 trial in the fourth quarter of 2016 with the objectives of: (1) assessing the 16-week efficacy of VTP-43742 in moderate to severe psoriasis patients; (2) assessing the safety of the

Vitae Pharmaceuticals, Inc.	Tel: (215) 461-2000
502 West Office Center Drive	Fax: (215) 461-2006
Fort Washington, PA 19034	www.vitaepharma.com

product candidate in a larger population and over a longer treatment period; and (3) positioning VTP-43742 to begin pivotal trials as soon as practicable after the completion of the Phase 2 clinical trial, if successful. Vitae expects to report top-line data from this trial in the second half of 2017.

VTP-45489 in Autoimmune Disorders

·Vitae is advancing VTP-45489, its second RORγt inhibitor, into the clinic. Vitae expects to initiate a Phase 1 single ascending dose clinical trial in normal healthy volunteers during the third quarter of 2016.

New Contour® Program

·Animal proof-of-principle achieved in a new target program. Initial lead candidate selected to advance into preclinical development.

Corporate Update:

·Appointed Carole Sable, M.D., as Chief Medical Officer. Dr. Sable will oversee the clinical development of Vitae’s pipeline, including VTP-43742 and VTP-38543. Dr. Sable brings to Vitae more than 20 years of diverse clinical development and executive management experience, having been involved in all phases of clinical research.

·Appointed Daniel M. Junius to Vitae’s Board of Directors. Mr. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc. and brings both executive and prior board experience to Vitae’s Board of Directors.

Financial Results:

·Operating Expense. Total operating expenses for the second quarter of 2016 were $10.5 million, compared with $10.0 million for the second quarter of 2015.

·Research and development expenses were $7.9 million for the second quarter of 2016, compared with $7.8 million for the second quarter of 2015. The slight increase was largely attributable to expenses related to preclinical programs, the atopic dermatitis program, discovery efforts, stock-based compensation and compensation expense, partially offset by reduced manufacturing expenses resulting from the timing of development activities for the RORγt program.

·General and administrative expenses were $2.7 million for the second quarter of 2016, compared with $2.3 million for the second quarter of 2015. The increase was primarily due to an increase in legal fees, patent related expenses, stock-based compensation expense and compensation expenses.

·Net Loss. Vitae reported a net loss of $10.4 million, or $0.36 per diluted share, for the second quarter of 2016, compared with a net loss of $9.8 million, or $0.45 per diluted share, for the second quarter of 2015. The increase in net loss was primarily due to the increase in general and administrative expenses.

·Cash Position. As of June 30, 2016, Vitae had $77.4 million in cash, cash equivalents and marketable securities, compared with $59.4 million as of December 31, 2015. The increase in cash position was primarily a result of the completion of a follow-on public offering in March 2016, partially offset by cash outflows used in operating activities. Based on its current business plan, Vitae believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its projected operating requirements into the second half of 2018.

Expected Upcoming Events

·VTP-38543 in Atopic Dermatitis — Top-line proof-of-concept results from a Phase 2a clinical trial in mild to moderate atopic dermatitis patients in the fourth quarter of 2016.

·VTP-43742 in Autoimmune Disorders — Initiation of a 16-week Phase 2 trial in the fourth quarter of 2016.

·VTP-45489 in Autoimmune Disorders — Initiation of a Phase 1 single ascending dose trial in the third quarter of 2016.

Company to Host Conference Call

Vitae will host a conference call with slides today, August 3, 2016, at 4:30 p.m. EDT to discuss the Company’s financial results for the quarter ended June 30, 2016, and recent operational highlights. A question and answer session will follow Vitae’s remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international), and provide the conference ID 56375798, approximately five to 10 minutes ahead of the start of the call.

A live audio webcast of the call and accompanying slides will be available via the “Investor Relations” page of the Vitae website, www.vitaepharma.com. Please log on through Vitae’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast and accompanying slides will be archived on Vitae’s website for 90 days following the call.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORgt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.

For additional information, please visit the company’s website at www.vitaepharma.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, the development of Vitae’s clinical programs. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Vitae’s SEC filings, including, but not limited to, the risks that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vitae’s Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which are on file with the SEC and available on the SEC’s website at www.sec.gov. Additional factors may be set forth in Vitae’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2016, to be filed with the SEC in the third quarter of 2016

In addition to the risks described above and in Vitae’s other filings with the SEC, other unknown or unpredictable factors also could affect Vitae’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vitae undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

###

INVESTORS:

Vitae Pharmaceuticals, Inc.

Richard S. Morris, CPA

Chief Financial Officer

(215) 461-2000

rmorris@vitaerx.com

Westwicke Partners

John Woolford

(443) 213-0506

john.woolford@westwicke.com

MEDIA:

6 Degrees PR

Tony Plohoros

(908) 591-2839

tplohoros@6degreespr.com

Vitae Pharmaceuticals, Inc.

Statement of Operations (unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2016			2015			2016			2015
Collaborative revenues	$	3,274		$	161,588		$	54,627		$	311,827
Operating expenses:
Research and development	7,878,900			7,772,822			15,515,195			15,278,738
General and administrative	2,659,908			2,259,358			5,157,230			4,370,414
Total operating expenses	10,538,808			10,032,180			20,672,425			19,649,152
Loss from operations	(10,535,534		)	(9,870,592		)	(20,617,798		)	(19,337,325		)
Other income (expenses):
Other income	—			1,430			—			1,430
Interest income	125,487			107,820			200,024			182,013
Interest expense	—			—			—			(107,864		)
Loss on debt extinguishment	—			—			—			(206,678		)
Total other income (expenses)	125,487			109,250			200,024			(131,099		)
Net loss	$	(10,410,047	)	$	(9,761,342	)	$	(20,417,774	)	$	(19,468,424	)
Per share information:
Net loss per common share:
Basic	$	(0.36	)	$	(0.45	)	$	(0.79	)	$	(0.91	)
Diluted	$	(0.36	)	$	(0.45	)	$	(0.79	)	$	(0.91	)
Weighted-average number of common shares:
Basic	28,829,553			21,837,676			25,686,529			21,315,094
Diluted	28,829,553			21,837,676			25,686,529			21,315,094

Vitae Pharmaceuticals, Inc.

Selected Balance Sheet Data

	As of June 30,		As of December 31,
	2016		2015
	(unaudited)
Cash, cash equivalents and marketable securities	$	77,441,692	$	59,369,836
Working capital	72,373,126		53,807,249
Current liabilities	6,127,981		7,329,754
Common stock and APIC	267,404,963		228,463,162
Total stockholder’s equity	73,032,076		54,467,750

EX-99.2

Exhibit 99.2

Second Quarter 2016 Earnings Call August 3, 2016

Disclaimer Regarding Forward Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "opportunity," "proposition," "strategy," "potential," "plan" or the negative of these terms and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including the clinical plans for VTP-43742, VTP-38543 and VTP-45489 and preclinical plans for our potential future product candidates, the anticipated top-line results from the Phase 2a proof-of-concept clinical trial for VTP-38543, the potential 12 week efficacy and safety for VTP-43742 and Vitae’s projected cash runway. Actual results may be materially different. Certain information in this presentation is from previously published data and literature from prior psoriasis trials of other compounds. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the timing and success of preclinical studies and clinical trials; the ability to obtain and maintain regulatory approval of our product candidates; the scope, progress, expansion and costs of developing and commercializing our product candidates; our expectations regarding the amount and timing of our expenses and revenue; the sufficiency of our cash resources, plans for the use of our cash resources and needs for additional financing; our ability to adequately manufacture our product candidates and the raw materials utilized therein; our ability to obtain and maintain intellectual property protection for our product candidates; our expectations regarding competition; the size and growth of the potential markets for our product candidates and the ability to serve those markets; the rate and degree of market acceptance of any of our product candidates; our anticipated growth strategies; the anticipated trends and challenges in our business and the market in which we operate; our ability to establish and maintain development partnerships; our ability to attract or retain key personnel; our expectations regarding federal, state and foreign regulatory requirements; regulatory developments in the United States and foreign countries and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, which have been filed with the Securities and Exchange Commission (SEC) and are available on the SEC's website at www.sec.gov. Additional factors may be set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, to be filed with the SEC in the third quarter of 2016. All written and verbal forward-looking statements attributable to Vitae or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vitae cautions investors not to rely too heavily on the forward-looking statements Vitae makes or that are made on its behalf. The information in this presentation is provided only as of the date of this presentation, and Vitae undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Second Quarter 2016 Highlights Ongoing Ph 2a proof-of-concept trial with VTP-38543 in atopic dermatitis patients on track for top-line results in 4Q 2016 First-in-class, wholly owned LXR agonist, with potential for differentiated profile in treating mild-to-moderate atopic dermatitis patients Upcoming Ph 2 trial with VTP-43742 in moderate-to-severe psoriasis patients on track to initiate in 4Q 2016 Positive Ph 2a proof-of-concept results announced in late 1Q 2016 First-in-class, wholly owned RORt inhibitor, with potential for transformative profile in the oral treatment of autoimmune disorders Pipeline expanding New pipeline programs generated by Vitae’s proprietary discovery platform Contour®, positioning Vitae for incremental future value growth Strong cash position $77.4 million cash and cash equivalents as of June 30, 2016; projected cash runway into 2H 2018

VTP-38543 for Atopic Dermatitis Ph 2a Proof-of-Concept Trial Ongoing

Atopic Dermatitis Atopic dermatitis (AD) is the most common inflammatory disease Estimated to occur in 15-25% of children and 4-7% of adults Estimated up to 32 million patients with AD in the US (~90% mild-to-moderate) AD characterized by flares of intense itching, red and inflamed rash, dry skin Itching and skin appearance have a major impact on patients (and families) 63% report sleep impairment up to 2 hours daily; sleep loss affects school / work performance, often impacts other family members 60% of adolescents report school difficulties; teasing and bullying 29% report impaired personal relationships; high divorce rate observed 71% report feelings of exhaustion, frustration, resentment and helplessness Health related quality of life impairment exceeds that in asthma and epilepsy, comparable to renal disease or cystic fibrosis

Atopic Dermatitis Pathogenesis and Treatment Options Intertwining mechanisms create pathology: skin barrier compromise and increased inflammatory response Either can be the initiating factor Skin barrier compromise (outsidein) Genetic skin barrier defects (e.g. filaggrin) in up to 50% of AD patients, allowing irritants and allergens from environment in, triggering an inflammatory response Increased inflammatory response (insideout) Lesional over-expression of cytokines leads to broader immune response Inflammatory response triggers itch-scratch cycle; scratching causes physical breakdown of skin barrier Currently available AD drugs limited to anti-inflammatory action No therapies are available that address both aspects ; corticosteroids, the predominant therapy, actually thin skin with chronic use Drs. Leung and Guttman-Yassky, J Allergy Clin Immunology, October 2014

VTP-38543 Ph 2a Proof-of-Concept Trial Clinical Endpoints Physician assessment of clinical efficacy Patient assessment of clinical efficacy Itching frequency / intensity and sleep disruption Biomarker assessment of barrier and inflammatory markers Includes SREBP1c (lipid synthesis), ABCG1 (lipid secretion), keratin-16 and filaggrin (associated with keratinocyte differentiation) and IL-6 (pro-inflammatory cytokine) Cell histology and immunohistochemistry changes from skin biopsies Safety / tolerability and PK Scoring System Acronym Rationale Description Investigator’s Global Assessment IGA US basis for approval Simple 0-4 scale per patient* Severity Scoring of Atopic Dermatitis SCORAD EU basis for approval Comprehensive, systematized scoring 0-103 point scale Eczema Area and Severity Index EASI Gaining use in US Comprehensive, systematized scoring 0-72 point scale * IGA measures ‘responders’ - those achieving a rating of 0 (clear) or 1 (almost clear) and a minimum two point rating change

Randomized, double blind, placebo controlled trial with 100 mild-to-moderate atopic dermatitis patients (IGA score of 2 or 3) VTP-38543 applied topically twice daily for 4 weeks Topline clinical results expected in 4Q 2016 0.05% VTP-38543 20 patients 0.15% VTP-38543 20 patients 1.0% VTP-38543 + solubilizer 20 patients Vehicle only 20 patients Vehicle + solubilizer 20 patients VTP-38543 Ph 2a Proof-of-Concept Trial Design

VTP-43742 for Autoimmune Disorders Positive Ph 2a Results in 1Q 2016; Planning for Next Trial

VTP-43742 Phase 2a Proof-of-Concept Trial Results Clinical trial design Randomized, double blind, placebo controlled 4 week treatment of 34 moderate-to-severe psoriasis patients Positive efficacy signal Clear and consistent signal of efficacy from PASI score changes in both the 350mg and 700mg dose groups Comprehensive biomarker data supported observed clinical results PASI score improvement accelerated significantly in week 3, more in week 4 Generally well tolerated 350mg dose group safety and tolerability comparable to placebo Transaminase elevations observed in some patients in the 700mg dose group Results clinically validate RORt target; support ‘go’ decision to advance VTP-43742 in clinical development

Establish the full efficacy potential of VTP-43742 All currently available therapies require >12 weeks dosing to achieve full efficacy In the 4 week Ph 2a trial with VTP-43742, clinical improvement accelerated significantly in week 3, even more in week 4; indicates potential for increasing efficacy beyond 4 weeks Next Ph 2 trial with VTP-43742 will be 16 weeks duration Further elaborate the safety / tolerability profile of VTP-43742 Efficiently enable VTP-43742 to proceed into a pivotal trial next, if Ph 2 trial successful Development Goal: to develop VTP-43742 as a transformative ‘best oral agent for the treatment of multiple autoimmune disorders, starting with psoriasis’ i.e. highly effective, safe, well tolerated, once daily oral therapy VTP-43742 Next Phase 2 Trial Design: Key Objectives

Pipeline

Pipeline Additional Assets Generated by Contour® VTP-45489 / RORt Inhibitor Company leveraging its global leadership in RORt science, and its recent clinical validation of the target, by expanding its presence in the space VTP-45489 chemically distinct from VTP-43742 Company expects to advance VTP-45489 into a Ph 1a single ascending dose clinical trial in 3Q 2016 VTP-36951 / BACE Inhibitor Company intends to hold VTP-36951 investment, pending results from Merck’s first-in-class BACE program Ph 3 outcomes trial results, which Merck has stated is expected in 2017

Pipeline Additional Assets Generated by Contour® Contour® is Vitae’s proprietary structure-based drug design (SBDD) platform Vitae applies Contour® to targets with these characteristics Known, relatively well validated biology High unmet medical need Specialty therapeutic category Difficult-to-drug target with significant technical hurdles to overcome Animal proof-of-principle achieved in a new target program Initial lead candidate selected to advance into pre-clinical development

For the three months ended: (in millions) June 30, 2016 June 30, 2015 Variance R&D expense $ 7.9 $ 7.8 $ 0.1 G&A expense 2.7 2.3 0.4 Total operating expense 10.5 10.0 0.5 Net loss (10.4) (9.8) (0.6) Vitae believes current cash levels will enable company to operate into 2H 2018 based upon on current business plan Selected Financial Statement Data (unaudited) (in millions) June 30, 2016 December 31, 2015 Variance Cash, cash equivalents and marketable securities $ 77.4 $ 59.4 $ 18.0

Near-Term Pipeline Milestones Remainder of 2016 Program Indication Preclin Dev Ph 1 POC Ph 2 WW Rights Next Expected Milestone VTP-43742 RORt Inhibitor Psoriasis, Autoimmune Disorders Vitae Initiation of Ph 2 4Q 2016 VTP-38543 LXR Agonist Atopic Dermatitis Vitae Top-line POC results 4Q 2016 VTP-45489 RORt Inhibitor Autoimmune Diseases Vitae Initiation of Ph 1a 3Q 2016 VTP-36951 BACE Inhibitor Alzheimer’s Disease Vitae Hold New Target Novel MOA Undisclosed Vitae Initiation of preclinical development 3Q 2016 $77.4 million cash and cash equivalents as of June 30, 2016; projected cash runway into 2H 2018